Patients with autonomic symptoms after long-term benzodiazepine use — orthostatic intolerance, palpitations, temperature dysregulation, GI dysmotility, urinary dysfunction, sweating abnormalities — are sometimes referred for formal autonomic function testing (AFT) to objectively characterize the problem. The results often do not match the intensity of the clinical picture. Patients who feel substantially disabled by autonomic symptoms frequently receive reports showing “mild” or “minimal” abnormalities, or even findings within the normal range on most parameters. This mismatch is a source of frustration for patients and, for some clinicians, becomes evidence that the symptoms are not as real as the patient believes. Neither interpretation is quite right, and understanding what AFT can and cannot detect explains the mismatch.
What AFT Actually Measures
Autonomic function testing is a panel of studies assessing different components of autonomic control. A typical comprehensive evaluation includes several elements.
Tilt-table testing. Assesses heart rate and blood pressure response to passive head-up tilt. Identifies orthostatic hypotension (a sustained drop in blood pressure on standing), postural tachycardia syndrome (POTS — sustained heart rate increase of 30 beats per minute or more on standing without hypotension), and neurocardiogenic syncope.
Heart rate variability with deep breathing. Measures the cardiovagal response — the expected heart rate acceleration on inhalation and deceleration on exhalation. Reduced variability indicates impaired parasympathetic control.
Valsalva maneuver. Assesses both sympathetic and parasympathetic responses through the stereotyped blood pressure and heart rate changes during and after forced exhalation against a closed glottis.
Quantitative sudomotor axon reflex test (QSART). Measures sweat response at defined skin sites to assess postganglionic sympathetic sudomotor function. Abnormal in length-dependent autonomic neuropathies and in some focal neuropathies.
Thermoregulatory sweat test (TST). Whole-body sweat response to controlled heat challenge; more comprehensive assessment of sweating patterns.
Supine and standing catecholamines. Useful in POTS evaluation and in distinguishing hyperadrenergic from other forms.
The panel is designed to characterize autonomic function systematically and to identify specific patterns suggesting particular diagnoses: pure autonomic failure, multiple system atrophy, diabetic autonomic neuropathy, POTS, various peripheral autonomic neuropathies.
What AFT Shows in Benzodiazepine-Related Dysautonomia
Several patterns are common.
POTS-type findings. Many patients with benzodiazepine withdrawal-related autonomic symptoms meet diagnostic criteria for POTS on tilt-table testing, with heart rate increases of 30 beats per minute or more on standing in the absence of significant orthostatic hypotension.
Reduced heart rate variability. Parasympathetic dysfunction with reduced heart rate variability and blunted deep-breathing responses is frequently documented.
Hyperadrenergic features. Elevated standing norepinephrine, exaggerated blood pressure lability, and excessive heart rate response to minimal stimuli are common.
Normal or near-normal QSART and TST. The sudomotor system is typically not abnormal on these tests in withdrawal-related dysautonomia, in contrast to structural peripheral autonomic neuropathies where these are often abnormal.
Normal structural workup. Paraneoplastic panels, ganglionic acetylcholine receptor antibodies, and other antibody studies are typically negative.
In summary: the pattern is functional autonomic dysfunction, predominantly in the hyperadrenergic or mixed direction, without the structural peripheral nerve involvement of conditions such as diabetic autonomic neuropathy or immune-mediated autonomic neuropathy.
What AFT Does Not Show
Several features of the clinical picture are real but are not captured well by standard AFT.
Temporal variability. A patient whose autonomic symptoms fluctuate substantially across days or weeks may be tested on a relatively good day, producing results that under-represent the typical burden.
Symptom severity. A patient with modest objective findings can still be substantially disabled by the subjective experience of autonomic symptoms. The tests measure physiologic parameters, not symptom burden, and the correlation is imperfect.
Central autonomic dysregulation. Much of the dysautonomia in benzodiazepine withdrawal is driven by central, supraspinal dysregulation rather than peripheral autonomic damage. Tests designed to identify structural peripheral deficits may look relatively normal even when central autonomic control is substantially impaired.
Episodic autonomic phenomena. Episodes of flushing, hot flashes, palpitations, or gastrointestinal phenomena may be completely absent during the testing period and therefore not captured.
Mast cell and neuroimmune contributions. The autonomic picture in a subset of patients has contributions from mast cell destabilization and neuroinflammation that AFT does not directly assess.
The underlying limitation is that AFT was developed to characterize specific structural autonomic diseases and related conditions. Functional autonomic dysregulation from a pharmacologic withdrawal syndrome is recognizable on some components of the test panel but is not the condition the tests were designed for.
What a Positive AFT Is Good For
Objective documentation serves several purposes.
Establishing that the symptoms have a physiologic correlate. For patients who have been dismissed or assessed as having purely psychological symptoms, a tilt-table confirming POTS or a documented reduction in heart rate variability provides an anchor that redirects the clinical conversation.
Supporting disability and insurance processes. Documentation of measurable dysautonomia has practical value in employment accommodation, disability claims, and insurance coverage of related treatments.
Guiding specific therapy. A documented POTS pattern justifies interventions specific to POTS (fluid and salt, compression, ivabradine, beta blockers in selected patients). Documented orthostatic hypotension justifies interventions specific to that (fludrocortisone, midodrine). Without documentation, the selection of autonomic-directed therapy is more speculative.
Excluding structural disease. Normal QSART and normal antibody panels reduce the prior for immune-mediated autonomic neuropathy or paraneoplastic conditions that would require different treatment.
What a Negative AFT Does and Does Not Mean
A patient with a largely normal AFT result still has their symptoms. The result means:
Structural autonomic disease is unlikely. Peripheral autonomic neuropathies and the identifiable structural causes of dysautonomia are not driving the picture.
Functional dysautonomia is not excluded. Central autonomic dysregulation, fluctuating peripheral function, and episodic phenomena are not reliably captured by a single testing session.
Management follows from the clinical picture rather than the test. A clinician who dismisses symptoms on the basis of a normal AFT is working from a framework in which only identifiable structural disease counts, which is not how functional autonomic dysfunction operates.
What to Ask For
For patients considering AFT in the context of benzodiazepine withdrawal, several practical requests matter.
Schedule the test during a period of typical symptom burden rather than an unusually good window. Testing when symptoms are mild produces results that do not reflect the usual clinical state.
Ensure the panel includes tilt-table with catecholamines and heart rate variability assessment. These are the components most likely to produce relevant positive findings in this population.
Request the report include specific numeric values, not only categorical interpretations. A heart rate increase of 28 beats per minute on standing — just under the POTS threshold — is clinically meaningful even if it does not meet criteria. Raw values allow nuanced clinical interpretation.
Discuss the results in the context of the benzodiazepine history. An autonomic specialist unfamiliar with benzodiazepine-related dysautonomia may interpret findings in isolation; a review that places results in the withdrawal context produces more useful conclusions.
The Underlying Point
Autonomic function testing is useful for characterizing dysautonomia after long-term benzodiazepine use, particularly when it documents POTS or related patterns that justify specific management. It is not a definitive test. A normal result does not establish that the symptoms are not autonomic in origin; it establishes that the specific patterns the test was designed to detect are not prominent. The clinical picture remains the primary data source; AFT supplements it without replacing it, and the combined information is what should drive management.